Agendia
Agendia to Distribute Inivata Liquid Biopsy Breast Cancer Test in North America, Europe
Agendia will receive co-exclusive rights to distribute Inivata's RaDaR assay for minimal residual disease and relapse detection in Europe and North America.
FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
PathoNext to Offer Agendia's Breast Cancer Recurrence Assays in Germany
PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.